Effects of phosphatidylinositol 3-kinase inhibitor
on human cervical carcinoma cells

doi:10.1007/s11684-009-0067-9

Front. Med.

2009, Vol. 3

Issue (3) : 341-346 https://doi.org/10.1007/s11684-009-0067-9

Research articles

Effects of phosphatidylinositol 3-kinase inhibitor on human cervical carcinoma cells

Yuan ZHANG MD , Xiaoyan ZHANG MM , Yanhui LI MM , Xuan DU MM , Zehua WANG MD, PhD , Hongbo WANG MD ,

Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China;

Download: PDF(145 KB)
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Abstract Phosphatidylinositol 3-kinase (PI3K) is a crucial cell survival pathway implicated in tumorigenesis because of its role in stimulating cell proliferation and suppressing apoptosis. This study was to investigate the regulation of proliferation and apoptosis by LY294002, an inhibitor of PI3K in cervical cancer cells and the expression of FLICE-like inhibitory protein (c-FLIP) in vitro. Human cervical cancer HeLa cells were used in this experiment and cultured. The cultured cells were treated with LY294002 at different concentrations (10, 25, 50 and 100µmol/L) for 6, 12, 24, and 48h before harvesting for evaluation. Cell viability was measured by 3-(4,5)-dimethylthiazol(-2-y1)-3,5-di-phenyltetrazoliumbromide (MTT) assay. Apoptosis was analyzed by flow cytometry. The expression of c-FLIP was detected by Western blot. Cell viability was inhibited by LY294002 significantly (P<0.05). Flow cytometry analysis revealed that cell apoptosis was significantly increased in the presence of LY294002 as compared with the control group. Although the expression of c-FLIP was increased in a short time, the expression of c-FLIP was markedly suppressed after the treatment of LY294002 for 48h. These results suggested that the PI3K/Akt signal pathway might be involved in the regulation of cell apoptosis in cervical cancer cells. Moreover, the regulation of c-FLIP expression through PI3K/Akt signal pathway in cervical cancer cells was observed in vitro.

Keywords human cervical cancer cells apoptosis phosphatidylinositol 3-kinase (PI3K)/Akt FLICE-like inhibitory protein

Issue Date: 05 September 2009

Cite this article:

Zehua WANG MD,Yuan ZHANG MD,Yanhui LI MM, et al. Effects of phosphatidylinositol 3-kinase inhibitor on human cervical carcinoma cells [J]. Front. Med., 2009, 3(3): 341-346.

URL:

https://academic.hep.com.cn/fmd/EN/10.1007/s11684-009-0067-9
https://academic.hep.com.cn/fmd/EN/Y2009/V3/I3/341

	Ma B B Y, Bristow R G, Kim J, Siu L L. Combined-modalitytreatment of solid tumors using radiotherapy and molecular targetedagents. J Clin Oncol, 2003, 21(14): 2760―2776 doi: 10.1200/JCO.2003.10.044
	Ullrich A, Schlessinger J. Signal transduction by receptorswith tyrosine kinase activity. Cell, 1990, 61(2): 203―212 doi: 10.1016/0092-8674(90)90801-K
	Blackhall F H, Pintilie M, Michael M, Leighl N, Feld R, Tsao M S, Shepherd R A. Expression and prognostic significance of kit, protein kinase B,and mitogen-activated protein kinase in patients with small cell lungcancer. Clin Cancer Res, 2003, 9(6): 2241―2247
	Fresno Vara J A, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M. PI3K/Akt signaling pathway and cancer. Cancer Treat Rev, 2004, 30(2): 193―204 doi: 10.1016/j.ctrv.2003.07.007
	Toker A, Cantley L C. Signaling through the lipidproducts of phosphoinositide-3-OH kinase. Nature, 1997, 387(6634): 673―676 doi: 10.1038/42648
	Yuan Z Q, Sun M, Feldman R I, Wang G, Ma X L, Jiang C, Coppola D, Nicosia S V, Cheng J Q. Frequentactivation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OHkinase/Akt pathway in human ovarian cancer. Oncogene, 2000, 19(19): 2324―2330 doi: 10.1038/sj.onc.1203598
	Choe G, Horvath S, Cloughesy T F, Crosby K, Seligson D, Palotie A, Inge L, Smith B L, Sawyers C L, Mischel P S. Analysis of the phosphatidylinositol3'-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res, 2003, 63(11): 2742―2746
	Harris C P, Lu X Y, Narayan G, Singh B, Murty V V, Rao P H. Comprehensive molecular cytogenetic characterization of cervicalcancer cell lines. Genes Chromosomes Cancer, 2003, 36(3): 233―241 doi: 10.1002/gcc.10158
	Ma Y Y, Wei S J, Lin Y C, Lung J C, Chang T C, Whang-Peng J, Liu J M, Yang D M, Yang W K, Shen C Y. PI3KCA as an oncogene in cervical cancer. Oncogene, 2000, 19(28): 2739―2744 doi: 10.1038/sj.onc.1203597
	Blagosklonny M V. Prospective strategies to enforce selectively cell death in cancercells. Oncogene, 2004, 23(16): 2967―2975 doi: 10.1038/sj.onc.1207520
	Wetzker R, Rommel C. Phosphoinositide 3-kinasesas targets for therapeutic intervention. Curr Pharm Des, 2004, 10(16): 1915―1922 doi: 10.2174/1381612043384402
	Kawaguchi W, Itamochi H, Kigawa J, Kanamori Y, Oishi T, Shimada M, Sato S, Shimogai R, Sato S, Terakawa N. Simultaneous inhibition ofthe mitogen-activated protein kinase and phosphatidylinositol 3'-kinasepathways enhances sensitivity to paclitaxel in ovarian carcinoma. Cancer Sci, 2007, 98(12): 2002―2008 doi: 10.1111/j.1349-7006.2007.00624.x
	Houston A, O'Connell J. The Fas signaling pathwayand its role in the pathogenesis of cancer. Curr Opin Pharmacol, 2004, 4(4): 321―326 doi: 10.1016/j.coph.2004.03.008
	Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer J L, Schröter M, Burns K, Mattmann C, Rimoldi D, French L E, Tschopp J. Inhibitionof death receptor signals by cellular FLIP. Nature, 1997, 388(6638): 190―195 doi: 10.1038/40657
	Krueger A, Baumann S, Krammer P H, Kirchhoff S, FLICE-inhibitoryproteins: regulators of death receptor-mediated apoptosis. Mol Cell Biol, 2001, 21(24): 8247―8254 doi: 10.1128/MCB.21.24.8247-8254.2001
	Mathas S, Lietz A, Anagnostopoulos I, Hummel F, Wiesner B, Janz M, Jundt F, Hirsch B, Jöhrens-Leder K, Vornlocher HP, Bommert K, Stein H, Dörken B. c-FLIP mediates resistanceof Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis. J Exp Med, 2004, 199(8): 1041―1052 doi: 10.1084/jem.20031080
	Panka D J, Mano T, Suhara T, Walsh K, Mier J W. Phosohatidylinositol 3-kinse/Akt activityregulates c-FLIP expression in tumor cells. J Biol Chem, 2001, 276(10): 6893―6896 doi: 10.1074/jbc.C000569200
	Roymans D, Slegers H. Phosphatidylinositol 3-kinasesin tumor progression. Eur J Biochem, 2001, 268(3): 487―498 doi: 10.1046/j.1432-1327.2001.01936.x
	Kim S H, Juhnn Y S, Kang S. Human papillomavirus 16 E5 up-regulates the expressionof vascular endothelial growth factor through the activation of epidermalgrowth factor receptor, MEK/ERK1, 2 and PI3K/Akt. Cell Mol Life Sci, 2006, 63(7,8): 930―938
	Zhang X Y, Zhang H Y, Zhang P N, Lu X, Sun H. Elevated phosphatidylinositol 3-kinaseactivation and its clinicopathological significance in cervical cancer. Eur J Obstet Gynecol Reprod Biol, 2008, 139(2): 237―244 doi: 10.1016/j.ejogrb.2007.12.021
	Krystal G W, Sulanke G, Litz J. Inhibition of phosphatidylinositol 3-kinase-Akt signalingblocks growth, promotes apoptosis, and enhances sensitivity of smallcell lung cancer cells to chemotherapy. Mol Cancer Ther, 2002, 1(11): 913―922
	Xu Q, Simpson S E, Scialla T J, Bagg A, Carroll M. Survival of acute myeloid leukemia cellsrequires PI3 kinase activation. Blood, 2003,102(3): 972―980 doi: 10.1182/blood-2002-11-3429
	Lee C M, Fuhrman C B, Planelles V, Tolley H D, Green C L, Zempolich K A. Phosphatidylinositol 3-kinase inhibition by LY294002radiosensitizes human cervical cancer cell lines. Clin Cancer Res, 2006, 12(1): 250―256 doi: 10.1158/1078-0432.CCR-05-1084
	Fuhrman C B, Kilgore J, LaCoursiere Y D, Lee C M, Milash B A, Soisson A P, Zempolich KA.Radiosensitization of cervical cancer cells via double-strand DNAbreak repair inhibition. Gynecol Oncol, 2008, 110(1): 93―98 doi: 10.1016/j.ygyno.2007.08.073
	Kang Y C, Kim K M, Lee K S. Serum bioactive lysophospholipids prevent TRAIL-inducedapoptosis via PI3K/Akt-dependent cFLIP expression and Bad phosphorylation. Cell Death Differ, 2004, 11(12): 1287―1298 doi: 10.1038/sj.cdd.4401489
	Davies C C, Mason J, Wakelam M J, Young L S, Eliopoulos A G. Inhibition of phosphatidylinositol3-kinase- and ERK MAPK-regulated protein synthesis reveals the pro-apoptoticproperties of CD40 ligation in carcinoma cells. J Biol Chem, 2004, 279(2): 1010―1019 doi: 10.1074/jbc.M303820200
	Martelli A M, Tazzari P L, Tabellini G. A new selective AKT pharmacological inhibitor reducesresistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid,and ionizing radiation of human leukemia cells. Leukemia, 2003, 17(9): 1794―1805 doi: 10.1038/sj.leu.2403044
	Kondo G, Iwase M, Watanabe H, Uchida M, Takaoka S, Ohashi M, Nagumo M. Enhancementof susceptibility to Fas-mediated apoptosis in oral squamous cellcarcinoma cells by phosphatidylinositol 3-kinase inhibitor. Oral Oncol, 2006, 42(7): 745―752 doi: 10.1016/j.oraloncology.2005.11.015
	Moriyama H, Yonehara S. Rapid up-regulation of c-FLIPexpression by BCR signaling through the PI3K/Akt pathway inhibitssimultaneously induced Fas-mediated apoptosis in murine B lymphocytes. Immunol Lett, 2007, 15, 109(1): 36―46

[1]	Qiuxia Han, Hanyu Zhu, Xiangmei Chen, Zhangsuo Liu. Non-genetic mechanisms of diabetic nephropathy[J]. Front. Med., 2017, 11(3): 319-332.
[2]	Hui XIAO PhD, Ming TIAN MM, Junna GE MM, Xin Wei MD, Zhaoming LI MM, Xiaolan LI MS, Deding TAO PhD, Junbo HU MD, Jianping GONG MD, . The role of CDK1 siRNA interference in cell cycle and cell apoptosis[J]. Front. Med., 2009, 3(4): 384-389.
[3]	Dixin LI MM , Hongbing ZENG MD , Chunyang JI MM , . Effect of pirfenidone on renal tubulointerstitial fibrosis[J]. Front. Med., 2009, 3(3): 316-322.
[4]	Qiong CHEN, Qing YU, Yuhu SONG, Peiyuan Li, Ying CHANG, Zhijun WANG, Lifeng LIU, Wei WU, Jusheng LIN. Cloning of human XAF1 gene promoter and assay of its transcription activity in a variety of cell lines[J]. Front Med Chin, 2009, 3(2): 148-152.
[5]	Jianwen REN, Zhenhui PENG, Birong GUO, Min PAN. Celecoxib in combination with retinoid CD437 inhibits melanoma A375 cell in vitro[J]. Front Med Chin, 2009, 3(1): 108-112.
[6]	ZHANG Shilong, ZENG Fuqing, PENG Shibo, WANG Liang. Effect on proliferation and apoptosis of T24 cell lines via silencing DNMT1 with RNA interference[J]. Front. Med., 2008, 2(4): 374-379.
[7]	ZHAN Rong, YU Qinghong, HUANG Haobo. Effect of arsenic trioxide on proliferation and apoptosis of U266 cells and its relationship with the expression variation of VEGF[J]. Front. Med., 2008, 2(4): 356-360.
[8]	LU Yi, QU Bo, LIU Chang, YU Liang, Liu Xuemin, WANG Haohua, JIANG An, ZHANG Xiaogang. Mechanism of hepatocellular damage in rat caused by low serum selenium[J]. Front. Med., 2008, 2(3): 255-258.
[9]	SU Yuan, JIN Yang, ZHANG Xiaoju, ZHOU Qiong, BAI Ming, ZHU Liping. Impact of siRNA targeting pirh2 on proliferation and cell cycle control of the lung adenocarcinoma cell line A549[J]. Front. Med., 2007, 1(4): 359-363.
[10]	OUYANG Shan, ZHANG Qinghua, QIAO Fuyuan. Relationship between expression of hepatocyte grow factor and apoptosis of trophoblasts in hypertensive disorder complicating pregnancy[J]. Front. Med., 2007, 1(4): 386-389.
[11]	CAO Jie, LI Wanglin, XIA Jie, TANG Weibiao, WANG Hui, CHEN Xiwen, XIAO Huanqing, LI Yuyuan, CHEN Xiaoping, DU Hong, CHEN Shanming. Absence of FHIT expression is associated with apoptosis inhibition in colorectal cancer[J]. Front. Med., 2007, 1(2): 147-156.
[12]	TIAN Yongji, LI Guilin, GAO Jun, WANG Renzhi, KONG Yanguo, ZHANG Zhenxing, LI Shifang, TIAN Shiqiang, DOU Wanchen, ZHANG Bo. Construction of 6HRE-GFAP-Baxα system specific for glioma gene therapy[J]. Front. Med., 2007, 1(1): 49-53.

Viewed

Full text

Abstract

Cited

Shared

Discussed